AR123636A1 - Variantes de anticuerpos caninos - Google Patents

Variantes de anticuerpos caninos

Info

Publication number
AR123636A1
AR123636A1 ARP210102697A ARP210102697A AR123636A1 AR 123636 A1 AR123636 A1 AR 123636A1 AR P210102697 A ARP210102697 A AR P210102697A AR P210102697 A ARP210102697 A AR P210102697A AR 123636 A1 AR123636 A1 AR 123636A1
Authority
AR
Argentina
Prior art keywords
amino acid
variants
constant domain
acid sequence
vector
Prior art date
Application number
ARP210102697A
Other languages
English (en)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of AR123636A1 publication Critical patent/AR123636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una IgG modificada que comprende: un dominio constante de IgG canina que comprende al menos una sustitución de aminoácidos en comparación con un dominio constante de IgG canina de tipo silvestre, caracterizada porque dicha sustitución está en el residuo de aminoácido 434, numerado de acuerdo con el índice EU según Kabat. Reivindicación 37: Un vector caracterizado porque comprende la secuencia de ácidos nucleicos que codifica la secuencia de aminoácidos establecida en la SEQ ID Nº 1. Reivindicación 38: Una célula aislada caracterizada porque comprende el vector de acuerdo con la reivindicación 37.
ARP210102697A 2020-09-28 2021-09-28 Variantes de anticuerpos caninos AR123636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063084241P 2020-09-28 2020-09-28

Publications (1)

Publication Number Publication Date
AR123636A1 true AR123636A1 (es) 2022-12-28

Family

ID=78599123

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102697A AR123636A1 (es) 2020-09-28 2021-09-28 Variantes de anticuerpos caninos

Country Status (17)

Country Link
US (1) US20240010716A1 (es)
EP (1) EP4217384A2 (es)
JP (1) JP2023543262A (es)
KR (1) KR20230079148A (es)
CN (1) CN116438196A (es)
AR (1) AR123636A1 (es)
AU (1) AU2021349301A1 (es)
BR (1) BR112023005393A2 (es)
CA (1) CA3194936A1 (es)
CL (1) CL2023000878A1 (es)
CO (1) CO2023004102A2 (es)
EC (1) ECSP23030271A (es)
IL (1) IL301413A (es)
MX (1) MX2023003624A (es)
PE (1) PE20231374A1 (es)
TW (1) TW202229337A (es)
WO (1) WO2022067233A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250284A2 (en) * 2022-06-21 2023-12-28 Zoetis Services Llc Canine antibody mutants

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
EP1778728A2 (en) 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2011291462A1 (en) 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP3887397A1 (en) * 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
MX2021008144A (es) * 2019-01-03 2021-10-13 Invetx Inc Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体

Also Published As

Publication number Publication date
IL301413A (en) 2023-05-01
JP2023543262A (ja) 2023-10-13
AU2021349301A1 (en) 2023-08-24
WO2022067233A2 (en) 2022-03-31
MX2023003624A (es) 2023-04-11
CA3194936A1 (en) 2022-03-31
CO2023004102A2 (es) 2023-04-05
ECSP23030271A (es) 2023-07-31
KR20230079148A (ko) 2023-06-05
CN116438196A (zh) 2023-07-14
PE20231374A1 (es) 2023-09-07
BR112023005393A2 (pt) 2023-04-25
CL2023000878A1 (es) 2023-10-20
EP4217384A2 (en) 2023-08-02
WO2022067233A3 (en) 2022-05-27
US20240010716A1 (en) 2024-01-11
TW202229337A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
AR107444A1 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
CY1122509T1 (el) Πολυπεπτιδια χιμαιρικου παραγοντα viii και χρησεις αυτων
MX2022011309A (es) Receptores de celulas t.
ES2545895T3 (es) Proteína de fusión anticancerígena
EA201691111A1 (ru) Химерные белки фактора viii и их применение
AR101936A1 (es) Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
CY1116458T1 (el) Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων
EA201590198A1 (ru) Комплекс фактора viii с xten и белком фактора фон виллебранда и его применение (варианты)
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
AR097405A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a cd123 y cd3 y usos de los mismos
RU2010116163A (ru) Вакцины и компоненты вакцин для подавления микробных клеток
CU20180129A7 (es) Anticuerpos anti-basigin humanizados
EA201270517A1 (ru) Микобактериальные вакцины
AR123636A1 (es) Variantes de anticuerpos caninos
AR101753A1 (es) COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
PE20121722A1 (es) Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia
PH12021550244A1 (en) Anti-btla antibody
EA201792274A1 (ru) Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения
PE20211742A1 (es) Anticuerpos agonistas de cd200r y sus usos
AR123645A1 (es) Variantes de anticuerpos felinos
AR076083A1 (es) Anticuerpo monoclonal anti-rhesus d
PE20211048A1 (es) Anticuerpos injertados con peptido natriuretico tipo c
MX2020002283A (es) Vacuna recombinante contra la enteropatia proliferativa en animales.
EA202092334A1 (ru) С-концевые варианты антител